Soleno Therapeutics Securities Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Source: PRnewswire
- Lawsuit Background: Hagens Berman reminds investors of the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO), with a lead plaintiff deadline of May 5, 2026, for those who purchased shares between March 26, 2025, and November 4, 2025.
- Safety Risk Allegations: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, resulting in significant investor losses due to concealed risks.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 results admitting disruptions in DCCR's launch, leading to a 27% drop in stock price in a single day, reflecting market disappointment in the company's prospects.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as whistleblowers may receive rewards of up to 30% of any successful SEC recovery, further advancing legal actions against Soleno.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
